| Code | CSB-RA624122MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to timolumab, targeting AOC3 (amine oxidase copper-containing 3), also known as vascular adhesion protein-1 (VAP-1) or semicarbazide-sensitive amine oxidase (SSAO). AOC3 is a multifunctional enzyme expressed on endothelial cells that plays crucial roles in leukocyte trafficking and inflammation by facilitating immune cell adhesion and extravasation into tissues. Through its enzymatic activity, AOC3 catalyzes the oxidative deamination of primary amines, generating hydrogen peroxide, aldehydes, and ammonia as byproducts that contribute to oxidative stress and tissue damage. This protein has been implicated in various inflammatory and metabolic disorders, including diabetes complications, liver fibrosis, cardiovascular disease, and chronic inflammatory conditions.
Timolumab represents an investigational therapeutic antibody designed to inhibit AOC3 function and reduce pathological inflammation. This biosimilar antibody serves as a valuable research tool for investigating AOC3-mediated pathways, studying leukocyte migration mechanisms, and exploring potential therapeutic interventions in inflammation-related diseases. It enables researchers to examine the role of AOC3 in disease models and validate therapeutic targets in preclinical studies.
There are currently no reviews for this product.